InvestorsHub Logo
Followers 38
Posts 2971
Boards Moderated 0
Alias Born 10/07/2012

Re: revenue_monster post# 239820

Wednesday, 10/21/2015 6:51:09 AM

Wednesday, October 21, 2015 6:51:09 AM

Post# of 346050

Hmmm so phase 3's do fail to meet end points. Scary

NOT comparable to PPHM at all. What is scary is the lengths companies go to to justify moving forward with some clinical studies when they have no business doing so - unfortunately putting patients at risk.

Here is an article by Adam explaining why Ganetespib was highly suspect and likely to fail - the article is from 2013 !!! and was based on the Phase II data.


http://www.thestreet.com/story/12084402/1/time-is-no-friend-to-syntas-lung-cancer-drug.html

Time Is No Friend To Synta's Lung Cancer Drug

By Adam Feuerstein Follow | 10/27/13 - 05:12 PM EDT

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News